Results 211 to 220 of about 131,342 (265)
Some of the next articles are maybe not open access.
Modern Rheumatology Case Reports, 2022
Thrombotic microangiopathy is characterised by endothelial cell injury, intravascular platelet-fibrin thrombi, and vascular damage, leading to acute kidney injury, thrombocytopenia, and microangiopathic haemolytic anaemia.
Fumiya Kitamura +11 more
semanticscholar +1 more source
Thrombotic microangiopathy is characterised by endothelial cell injury, intravascular platelet-fibrin thrombi, and vascular damage, leading to acute kidney injury, thrombocytopenia, and microangiopathic haemolytic anaemia.
Fumiya Kitamura +11 more
semanticscholar +1 more source
Transfusion and Apheresis Science, 2011
Thrombotic microangiopathy (TMA) is a histopathological feature of various diseases including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). There are many secondary causes of TMA, many of them could mimic TTP or HUS. This article presents a short overview on TMA.
M, Mörtzell +18 more
openaire +2 more sources
Thrombotic microangiopathy (TMA) is a histopathological feature of various diseases including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). There are many secondary causes of TMA, many of them could mimic TTP or HUS. This article presents a short overview on TMA.
M, Mörtzell +18 more
openaire +2 more sources
European Journal of Internal Medicine, 2000
The term 'thrombotic microangiopathy' (TMA) describes syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation. The term 'hemolytic uremic syndrome' (HUS) has entered clinical use to describe childhood cases of TMA dominated by renal impairment, while ...
, Pisoni, , Remuzzi
openaire +2 more sources
The term 'thrombotic microangiopathy' (TMA) describes syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation. The term 'hemolytic uremic syndrome' (HUS) has entered clinical use to describe childhood cases of TMA dominated by renal impairment, while ...
, Pisoni, , Remuzzi
openaire +2 more sources
Clinical Nephrology, 2021
BACKGROUND Bevacizumab is a recombinant monoclonal antibody against the vascular endothelial growth factor A (VEGF-A) ligand that is used in the management of various solid malignancies.
Rachel Hilburg +6 more
semanticscholar +1 more source
BACKGROUND Bevacizumab is a recombinant monoclonal antibody against the vascular endothelial growth factor A (VEGF-A) ligand that is used in the management of various solid malignancies.
Rachel Hilburg +6 more
semanticscholar +1 more source
International Immunopharmacology
BACKGROUND Thrombotic microangiopathy (TMA) is associated with carfilzomib, and knowledge of carfilzomib-induced TMA is based mainly on case reports.
Weilun Fang +4 more
semanticscholar +1 more source
BACKGROUND Thrombotic microangiopathy (TMA) is associated with carfilzomib, and knowledge of carfilzomib-induced TMA is based mainly on case reports.
Weilun Fang +4 more
semanticscholar +1 more source
A case of thrombotic microangiopathy/microangiopathies
Blood Coagulation & Fibrinolysis, 2014We report a case of Streptococcus pneumonia sepsis-associated disseminated intravascular coagulation (DIC) with features of acute renal failure and microvascular thrombosis characterized by skin purpura and bilateral foot necrosis. The persistence of laboratory features of microangiopathic hemolytic anemia despite aggressive correction of DIC ...
Zhineng J, Yang +2 more
openaire +2 more sources
2019
Abstract The thrombotic microangioapathy (TMA) syndromes are characterized by concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic anemia, and ischemic end organ dysfunction often of the kidneys. While several of their features overlap in terms of clinical presentation, the pathophysiology and underlying causes ...
Harpreet Singh +2 more
+4 more sources
Abstract The thrombotic microangioapathy (TMA) syndromes are characterized by concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic anemia, and ischemic end organ dysfunction often of the kidneys. While several of their features overlap in terms of clinical presentation, the pathophysiology and underlying causes ...
Harpreet Singh +2 more
+4 more sources
La Revue du praticien, 2013
Thrombotic microangiopathies (TMA) encompass various diseases characterized by a microangiopathic hemolytic anemia, platelet clumping, and organ failure of variable severity. Thrombotic thrombocytopenic purpura (TTP) is a particularly severe form of TMA characterized by systemic organ failure which results from a severe defect in ADAMTS13, a plasma ...
Agnes B. Fogo +4 more
openaire +3 more sources
Thrombotic microangiopathies (TMA) encompass various diseases characterized by a microangiopathic hemolytic anemia, platelet clumping, and organ failure of variable severity. Thrombotic thrombocytopenic purpura (TTP) is a particularly severe form of TMA characterized by systemic organ failure which results from a severe defect in ADAMTS13, a plasma ...
Agnes B. Fogo +4 more
openaire +3 more sources
Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily
British Journal of Haematology, 2020Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble more the pathophysiology and phenotype of complement-mediated thrombotic micoangiopathies (TMA), rather than sepsis-induced coagulopathy or disseminated intravascular ...
E. Gavriilaki, R. Brodsky
semanticscholar +1 more source
[Thrombotic microangiopathies].
Hamostaseologie, 2009Thrombotic microangiopathies are disorders of microvascular occlusion and are characterized by thrombocytopenia and microangiopathic haemolytic anaemia. Varying additional signs and symptoms of organ ischaemia may be present. Thrombotic microangiopathies are pathophysiologically heterogenous disorders and include primarily thrombotic thrombocytopenic ...
Nielsen, O.J., Friis-Hansen, L.
+6 more sources